» Articles » PMID: 18060041

Adoptive Transfer of Effector CD8+ T Cells Derived from Central Memory Cells Establishes Persistent T Cell Memory in Primates

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2007 Dec 7
PMID 18060041
Citations 479
Authors
Affiliations
Soon will be listed here.
Abstract

The adoptive transfer of antigen-specific T cells that have been expanded ex vivo is being actively pursued to treat infections and malignancy in humans. The T cell populations that are available for adoptive immunotherapy include both effector memory and central memory cells, and these differ in phenotype, function, and homing. The efficacy of adoptive immunotherapy requires that transferred T cells persist in vivo, but identifying T cells that can reproducibly survive in vivo after they have been numerically expanded by in vitro culture has proven difficult. Here we show that in macaques, antigen-specific CD8(+) T cell clones derived from central memory T cells, but not effector memory T cells, persisted long-term in vivo, reacquired phenotypic and functional properties of memory T cells, and occupied memory T cell niches. These results demonstrate that clonally derived CD8+ T cells isolated from central memory T cells are distinct from those derived from effector memory T cells and retain an intrinsic capacity that enables them to survive after adoptive transfer and revert to the memory cell pool. These results could have significant implications for the selection of T cells to expand or to engineer for adoptive immunotherapy of human infections or malignancy.

Citing Articles

Tumor-specific CD8 T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytes.

Zawidzka E, Biavati L, Thomas A, Zanettini C, Marchionni L, Leone R J Immunother Cancer. 2025; 13(2).

PMID: 40010772 PMC: 11865787. DOI: 10.1136/jitc-2024-009367.


Adoptive T Cell Therapy Targeting MAGE-A4.

Chandora K, Chandora A, Saeed A, Cavalcante L Cancers (Basel). 2025; 17(3).

PMID: 39941782 PMC: 11815873. DOI: 10.3390/cancers17030413.


Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen.

Chih Y, Dietsch A, Koopmann P, Ma X, Agardy D, Zhao B Nat Commun. 2025; 16(1):1262.

PMID: 39893177 PMC: 11787355. DOI: 10.1038/s41467-025-56547-w.


LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells.

Zhu S, Zuo S, Li C, You X, Jiang E, Feng X J Exp Clin Cancer Res. 2025; 44(1):25.

PMID: 39856752 PMC: 11763111. DOI: 10.1186/s13046-025-03273-2.


Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

Kuilman T, Schrikkema D, Gadiot J, Gomez-Eerland R, Bies L, Walker J Nat Commun. 2025; 16(1):649.

PMID: 39809767 PMC: 11733228. DOI: 10.1038/s41467-024-55420-6.


References
1.
Willinger T, Freeman T, Hasegawa H, McMichael A, Callan M . Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. J Immunol. 2005; 175(9):5895-903. DOI: 10.4049/jimmunol.175.9.5895. View

2.
Brentjens R, Latouche J, Santos E, Marti F, Gong M, Lyddane C . Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003; 9(3):279-86. DOI: 10.1038/nm827. View

3.
Kondo K, KANESHIMA H, Mocarski E . Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci U S A. 1994; 91(25):11879-83. PMC: 45339. DOI: 10.1073/pnas.91.25.11879. View

4.
Berger C, Blau C, Huang M, Iuliucci J, Dalgarno D, Gaschet J . Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood. 2003; 103(4):1261-9. DOI: 10.1182/blood-2003-08-2908. View

5.
Yee C, Thompson J, Byrd D, Riddell S, Roche P, Celis E . Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002; 99(25):16168-73. PMC: 138583. DOI: 10.1073/pnas.242600099. View